Plant-made pharmaceuticals for the prevention and treatment of autoimmune diseases: where are we?

References

• von Boehmer H, Melchers F. Checkpoints in lymphocyte development and autoimmune disease. Nat. Immunol.11(1), 14–20 (2010).
   PubMed Web of Science ®Google Scholar
• Mackay IR. Clustering and commonalities among autoimmune diseases. J. Autoimmun.33(3–4), 170–177 (2009).
   PubMed Web of Science ®Google Scholar
• Sakaguchi S. Naturally arising CD4+ regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu. Rev. Immunol.22, 531–562 (2004).
   PubMed Web of Science ®Google Scholar
• Garza KM, Agersborg SS, Baker E, Tung KS. Persistence of physiological self antigen is required for the regulation of self tolerance. J. Immunol.164(8), 3982–3989 (2000).
   Google Scholar
• Lernmark A, Falorni A. Immunology of insulin-dependent diabetes mellitus. In: Textbook of Diabetes. Pickup J, Williams G (Eds). Blackwell Science Ltd, Oxford, UK, 15.11–15.23 (1997).
   Google Scholar
• The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N. Engl. J. Med.329(14), 977–986 (1993).
   PubMed Web of Science ®Google Scholar
• Luo X, Herold KC, Miller SD. Immunotherapy of Type 1 diabetes: where are we and where should we be going? Immunity32(4), 488–499 (2010).
   PubMed Web of Science ®Google Scholar
• Firestein GS. Evolving concepts of rheumatoid arthritis. Nature423(6937), 356–361 (2003).
   PubMed Web of Science ®Google Scholar
• Goronzy JJ, Weyand CM. Developments in the scientific understanding of rheumatoid arthritis. Arthritis Res. Ther.11(5), 249 (2009).
   PubMed Web of Science ®Google Scholar
• Pratt AG, Isaacs JD, Mattey DL. Current concepts in the pathogenesis of early rheumatoid arthritis. Best Pract. Res. Clin. Rheumatol.23(1), 37–48 (2009).
   PubMedGoogle Scholar
• Baumgart DC, Carding SR. Inflammatory bowel disease: cause and immunobiology. Lancet369(9573), 1627–1640 (2007).
   PubMed Web of Science ®Google Scholar
• Ludvigsson J. Therapy with GAD in diabetes. Diabetes Metab. Res. Rev.25(4), 307–315 (2009).
   PubMed Web of Science ®Google Scholar
• Ludvigsson J, Faresjo M, Hjorth M et al. GAD treatment and insulin secretion in recent-onset type 1 diabetes. N. Engl. J. Med.359(18), 1909–1920 (2008).
   PubMed Web of Science ®Google Scholar
• Harrison LC. The prospect of vaccination to prevent Type 1 diabetes. Hum. Vaccin.1(4), 143–150 (2005).
   PubMed Web of Science ®Google Scholar
• Wolfraim LA. Treating autoimmune diseases through restoration of antigen-specific immune tolerance. Arch. Immunol. Ther. Exp. (Warsz.)54(1), 1–13 (2006).
   PubMed Web of Science ®Google Scholar
• Kong Q, Richter L, Yang YF, Arntzen CJ, Mason HS, Thanavala Y. Oral immunization with hepatitis B surface antigen expressed in transgenic plants. Proc. Natl Acad. Sci. USA98(20), 11539–11544 (2001).
   PubMed Web of Science ®Google Scholar
• Rigano MM, Sala F, Arntzen CJ, Walmsley AM. Targeting of plant-derived vaccine antigens to immunoresponsive mucosal sites. Vaccine1(7–8), 809–811 (2003).
   Google Scholar
• Boehm R. Bioproduction of therapeutic proteins in the 21st Century and the role of plants and plant cells as production platforms. Ann. NY Acad. Sci.1102, 121–134 (2007).
   PubMed Web of Science ®Google Scholar
• Chan SJ, Weiss J, Konrad M et al. Biosynthesis and periplasmic segregation of human proinsulin in Escherichia coli. Proc. Natl Acad. Sci. USA78(9), 5401–5405 (1981).
   PubMedGoogle Scholar
• Thim L, Hansen MT, Norris K et al. Secretion and processing of insulin precursors in yeast. Proc. Natl Acad. Sci. USA83(18), 6766–6770 (1986).
   PubMed Web of Science ®Google Scholar
• Wang Y, Liang ZH, Zhang YS et al. Human insulin from a precursor overexpressed in the methylotrophic yeast Pichia pastoris and a simple procedure for purifying the expression product. Biotechnol. Bioeng.73(1), 74–79 (2001).
   PubMed Web of Science ®Google Scholar
• Yanagita M, Nakayama K, Takeuchi T. Processing of mutated proinsulin with tetrabasic cleavage sites to bioactive insulin in the non-endocrine cell line, COS-7. FEBS Lett.311(1), 55–59 (1992).
   Google Scholar
• Nykiforuk CL, Boothe JG, Murray EW et al. Transgenic expression and recovery of biologically active recombinant human insulin from Arabidopsis thaliana seeds. Plant Biotechnol. J.4(1), 77–85 (2006).
   PubMed Web of Science ®Google Scholar
• Boothe JG, Nykiforuk CL, Kuhlman PA et al. Analytical characterization, safety and clinical bioequivalence of recombinant human insulin from transgenic plants. Presented at: American Diabetes Association’s 69th Scientific Sessions. New Orleans, LA, USA, 5–9 June 2009.
   Google Scholar
• Mett V, Shamloul AM, Hirai H, Zhou Z, Notkins A, Yusibov V. Engineering and expression of the intracellular domain of insulinoma-associated tyrosine phosphatase (IA-2ic), a Type 1 diabetes autoantigen, in plants. Transgenic Res.16(1), 77–84 (2007).
   Google Scholar
• Capitani G, De Biase D, Aurizi C, Gut H, Bossa F, Grutter MG. Crystal structure and functional analysis of Escherichia coli glutamate decarboxylase. EMBO J.22(16), 4027–4037 (2003).
   PubMed Web of Science ®Google Scholar
• Ma SW, Zhao DL, Yin ZQ et al. Transgenic plants expressing autoantigens fed to mice to induce oral immune tolerance. Nat. Med.3(7), 793–796 (1997).
   PubMed Web of Science ®Google Scholar
• Porceddu A, Falorni A, Ferradini N et al. Transgenic plants expressing human glutamic acid decarboxylase (GAD65), a major autoantigen in insulin-dependent diabetes mellitus. Mol. Breeding5(6), 553–560 (1999).
   Web of Science ®Google Scholar
• Avesani L, Falorni A, Tornielli GB et al. Improved in planta expression of the human islet autoantigen glutamic acid decarboxylase (GAD65). Transgenic Res.12(2), 203–212 (2003).
   PubMed Web of Science ®Google Scholar
• Avesani L, Vitale A, Pedrazzini E et al. Recombinant human GAD65 accumulates to high levels in transgenic tobacco plants when expressed as an enzymatically inactive mutant. Plant Biotechnol. J. DOI: 10.1111/j.1467–7652.2010.00514.x (2010) (Epub ahead of print).
   Google Scholar
• Hampe CS, Hammerle LP, Falorni A, Robertson J, Lernmark A. Site-directed mutagenesis of K396R of the 65 kDa glutamic acid decarboxylase active site obliterates enzyme activity but not antibody binding. FEBS Lett.488(3), 185–189 (2001).
   Google Scholar
• Wang X, Brandsma M, Tremblay R et al. A novel expression platform for the production of diabetes-associated autoantigen human glutamic acid decarboxylase (hGAD65). BMC Biotechnol.8, 87 (2008).
   PubMed Web of Science ®Google Scholar
• Morgan K, Turner SL, Reynolds I, Hajeer AH, Brass A, Worthington J. Identification of an immunodominant B-cell epitope in bovine type II collagen and the production of antibodies to type II collagen by immunization with a synthetic peptide representing this epitope. Immunology77(4), 609–616 (1992).
   PubMed Web of Science ®Google Scholar
• Staines NA, Harper N, Ward FJ, Malmstrom V, Holmdahl R, Bansal S. Mucosal tolerance and suppression of collagen-induced arthritis (CIA) induced by nasal inhalation of synthetic peptide 184–198 of bovine type II collagen (CII) expressing a dominant T cell epitope. Clin. Exp. Immunol.103(3), 368–375 (1996).
   PubMed Web of Science ®Google Scholar
• Myers LK, Seyer JM, Stuart JM, Terato K, David CS, Kang AH. T cell epitopes of type II collagen that regulate murine collagen-induced arthritis. J. Immunol.151(1), 500–505 (1993).
   PubMed Web of Science ®Google Scholar
• Krco CJ, Pawelski J, Harders J et al. Characterization of the antigenic structure of human type II collagen. J. Immunol.156(8), 2761–2768 (1996).
   PubMedGoogle Scholar
• Khare SD, Krco CJ, Griffiths MM, Luthra HS, David CS. Oral administration of an immunodominant human collagen peptide modulates collagen-induced arthritis. J. Immunol.155(7), 3653–3659 (1995).
   PubMedGoogle Scholar
• Zhu P, Li XY, Wang HK et al. Oral administration of type-II collagen peptide 250–270 suppresses specific cellular and humoral immune response in collagen-induced arthritis. Clin. Immunol.122(1), 75–84 (2007).
   PubMed Web of Science ®Google Scholar
• Hashizume F, Hino S, Kakehashi M et al. Development and evaluation of transgenic rice seeds accumulating a type II-collagen tolerogenic peptide. Transgenic Res.17(6), 1117–1129 (2008).
   Google Scholar
• Sarker S, Ogawa M, Takahashi M, Asasda K. The processing of a 57-kDa precursor peptide to subunits of rice glutelin. Plant Cell Physiol.27, 1579–1586 (1986).
   Google Scholar
• Moder KG, Nabozny GH, Luthra HS, David CS. Immunogenetics of collagen induced arthritis in mice: a model for human polyarthritis. Reg. Immunol.4(5), 305–313 (1992).
   Google Scholar
• Suzuki M, Uetsuka K, Suzuki M, Shinozuka J, Nakayama H, Doi K. Immunohistochemical study on type II collagen-induced arthritis in DBA/1J mice. Exp. Anim.46(4), 259–267 (1997).
   Google Scholar
• Myers LK, Brand DD, Ye XJ et al. Characterization of recombinant type II collagen: arthritogenicity and tolerogenicity in DBA/1 mice. Immunology95(4), 631–639 (1998).
   PubMed Web of Science ®Google Scholar
• Holmdahl R, Andersson EC, Andersen CB, Svejgaard A, Fugger L. Transgenic mouse models of rheumatoid arthritis. Immunol. Rev.169, 161–173 (1999).
   Google Scholar
• Garcia G, Komagata Y, Slavin AJ, Maron R, Weiner HL. Suppression of collagen-induced arthritis by oral or nasal administration of type II collagen. J. Autoimmun.13(3), 315–324 (1999).
   PubMedGoogle Scholar
• Folk JE, Finlayson JS. The epsilon-(g-glutamyl)lysine crosslink and the catalytic role of transglutaminases. Adv. Protein Chem.31, 1–133 (1977).
   PubMedGoogle Scholar
• Dieterich W, Ehnis T, Bauer M et al. Identification of tissue transglutaminase as the autoantigen of celiac disease. Nat. Med.3(7), 797–801 (1997).
   PubMed Web of Science ®Google Scholar
• Sblattero D, Berti I, Trevisiol C et al. Human recombinant tissue transglutaminase ELISA: an innovative diagnostic assay for celiac disease. Am. J. Gastroenterol.95(5), 1253–1257 (2000).
   PubMed Web of Science ®Google Scholar
• Osman AA, Richter T, Stern M et al. Production of recombinant human tissue transglutaminase using the baculovirus expression system, and its application for serological diagnosis of coeliac disease. Eur. J. Gastroenterol. Hepatol.14(11), 1217–1223 (2002).
   Google Scholar
• Blackwell PJ, Hill PG, Holmes GK. Autoantibodies to human tissue transglutaminase: superior predictors of coeliac disease. Scand. J. Gastroenterol.37(11), 1282–1285 (2002).
   PubMed Web of Science ®Google Scholar
• Shi Q, Kim SY, Blass JP, Cooper AJ. Expression in Escherichia coli and purification of hexahistidine-tagged human tissue transglutaminase. Protein Expr. Purif.24(3), 366–373 (2002).
   Google Scholar
• Sorrentino A, Schillberg S, Fischer R, Rao R, Porta R, Mariniello L. Recombinant human tissue transglutaminase produced into tobacco suspension cell cultures is active and recognizes autoantibodies in the serum of coeliac patients. Int. J. Biochem. Cell Biol.37(4), 842–851 (2005).
   Google Scholar
• Sorrentino A, Schillberg S, Fischer R, Porta R, Mariniello L. Molecular farming of human tissue transglutaminase in tobacco plants. Amino Acids36(4), 765–772 (2009).
   Google Scholar
• Sun JB, Rask C, Olsson T, Holmgren J, Czerkinsky C. Treatment of experimental autoimmune encephalomyelitis by feeding myelin basic protein conjugated to cholera toxin B subunit. Proc. Natl Acad. Sci. USA93(14), 7196–7201 (1996).
   PubMed Web of Science ®Google Scholar
• Holmgren J, Adamsson J, Anjuere F et al. Mucosal adjuvants and anti-infection and anti-immunopathology vaccines based on cholera toxin, cholera toxin B subunit and CpG DNA. Immunol. Lett.97(2), 181–188 (2005).
   PubMed Web of Science ®Google Scholar
• Sun JB, Czerkinsky C, Holmgren J. Mucosally induced immunological tolerance, regulatory T cells and the adjuvant effect by cholera toxin B subunit. Scand. J. Immunol.71(1), 1–11 (2010).
   PubMed Web of Science ®Google Scholar
• Frey A, Giannasca KT, Weltzin R et al. Role of the glycocalyx in regulating access of microparticles to apical plasma membranes of intestinal epithelial cells: implications for microbial attachment and oral vaccine targeting. J. Exp. Med.184(3), 1045–1059 (1996).
   PubMed Web of Science ®Google Scholar
• Carter JE 3rd, Odumosu O, Langridge WH. Expression of a ricin toxin B subunit: insulin fusion protein in edible plant tissues. Mol. Biotechnol.44(2), 90–100 (2010).
   PubMed Web of Science ®Google Scholar
• Arakawa T, Yu J, Chong DK, Hough J, Engen PC, Langridge WH. A plant-based cholera toxin B subunit-insulin fusion protein protects against the development of autoimmune diabetes. Nat. Biotechnol.16(10), 934–938 (1998).
   PubMed Web of Science ®Google Scholar
• Ruhlman T, Ahangari R, Devine A, Samsam M, Daniell H. Expression of cholera toxin B-proinsulin fusion protein in lettuce and tobacco chloroplasts – oral administration protects against development of insulitis in non-obese diabetic mice. Plant Biotechnol. J.5(4), 495–510 (2007).
   PubMed Web of Science ®Google Scholar
• Li D, O’Leary J, Huang Y, Huner NP, Jevnikar AM, Ma S. Expression of cholera toxin B subunit and the B chain of human insulin as a fusion protein in transgenic tobacco plants. Plant Cell Rep.25(5), 417–424 (2006).
   PubMed Web of Science ®Google Scholar
• Bot A, Smith D, Bot S et al. Plasmid vaccination with insulin B chain prevents autoimmune diabetes in nonobese diabetic mice. J. Immunol.167(5), 2950–2955 (2001).
   PubMed Web of Science ®Google Scholar
• Ma S, Huang Y, Yin Z, Menassa R, Brandle JE, Jevnikar AM. Induction of oral tolerance to prevent diabetes with transgenic plants requires glutamic acid decarboxylase (GAD) and IL-4. Proc. Natl Acad. Sci. USA101(15), 5680–5685 (2004).
   PubMed Web of Science ®Google Scholar
• Tepper RI, Pattengale PK, Leder P. Murine interleukin-4 displays potent anti-tumor activity in vivo. Cell57(3), 503–512 (1989).
   PubMed Web of Science ®Google Scholar
• Okabe M, Kuni-eda Y, Sugiwura T et al. Inhibitory effect of interleukin-4 on the in vitro growth of Ph1-positive acute lymphoblastic leukemia cells. Blood78(6), 1574–1580 (1991).
   PubMed Web of Science ®Google Scholar
• Ghoreschi K, Thomas P, Breit S et al. Interleukin-4 therapy of psoriasis induces Th2 responses and improves human autoimmune disease. Nat. Med.9(1), 40–46 (2003).
   PubMed Web of Science ®Google Scholar
• Rapoport MJ, Jaramillo A, Zipris D et al. Interleukin 4 reverses T cell proliferative unresponsiveness and prevents the onset of diabetes in nonobese diabetic mice. J. Exp. Med.178(1), 87–99 (1993).
   PubMed Web of Science ®Google Scholar
• van Kimmenade A, Bond MW, Schumacher JH, Laquoi C, Kastelein RA. Expression, renaturation and purification of recombinant human interleukin 4 from Escherichia coli. Eur. J. Biochem.173(1), 109–114 (1988).
   Google Scholar
• Solari R, Quint D, Obray H et al. Purification and characterization of recombinant human interleukin 4. Biological activities, receptor binding and the generation of monoclonal antibodies. Biochem. J.262(3), 897–908 (1989).
   Google Scholar
• Magnuson NS, Linzmaier PM, Reeves R, An G, HayGlass K, Lee JM. Secretion of biologically active human interleukin-2 and interleukin-4 from genetically modified tobacco cells in suspension culture. Protein Expr. Purif.13(1), 45–52 (1998).
   PubMed Web of Science ®Google Scholar
• Ma S, Huang Y, Davis A et al. Production of biologically active human interleukin-4 in transgenic tobacco and potato. Plant Biotechnol. J.3(3), 309–318 (2005).
   Google Scholar
• Wogensen L, Lee MS, Sarvetnick N. Production of interleukin 10 by islet cells accelerates immune-mediated destruction of b cells in nonobese diabetic mice. J. Exp. Med.179(4), 1379–1384 (1994).
   PubMed Web of Science ®Google Scholar
• Walsh SR, Shear NH. Psoriasis and the new biologic agents: interrupting a T-AP dance. CMAJ170(13), 1933–1941 (2004).
   PubMedGoogle Scholar
• Menassa R, Nguyen V, Jevnikar A, Brandle J. A self-contained system for the field production of plant recombinant interleukin-10. Mol. Breeding8, 177–185 (2001).
   Web of Science ®Google Scholar
• Menassa R, Kennette W, Nguyen V, Rymerson R, Jevnikar A, Brandle J. Subcellular targeting of human interleukin-10 in plants. J. Biotechnol.108(2), 179–183 (2004).
   PubMed Web of Science ®Google Scholar
• Menassa R, Du C, Yin ZQ et al. Therapeutic effectiveness of orally administered transgenic low-alkaloid tobacco expressing human interleukin-10 in a mouse model of colitis. Plant Biotechnol. J.5(1), 50–59 (2007).
   Google Scholar
• Scheinin T, Butler DM, Salway F, Scallon B, Feldmann M. Validation of the interleukin-10 knockout mouse model of colitis: antitumour necrosis factor-antibodies suppress the progression of colitis. Clin. Exp. Immunol.133(1), 38–43 (2003).
   Google Scholar
• Steidler L, Hans W, Schotte L et al. Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science289(5483), 1352–1355 (2000).
   PubMed Web of Science ®Google Scholar
• Patel J, Zhu H, Menassa R, Gyenis L, Richman A, Brandle J. Elastin-like polypeptide fusions enhance the accumulation of recombinant proteins in tobacco leaves. Transgenic Res.16(2), 239–249 (2007).
   PubMed Web of Science ®Google Scholar
• Wakkach A, Cottrez F, Groux H. Can interleukin-10 be used as a true immunoregulatory cytokine? Eur. Cytokine Netw.11(2), 153–160 (2000).
   PubMed Web of Science ®Google Scholar
• Moore KW, de Waal Malefyt R, Coffman RL, O’Garra A. Interleukin-10 and the interleukin-10 receptor. Annu. Rev. Immunol.19, 683–765 (2001).
   PubMed Web of Science ®Google Scholar
• Bortesi L, Rossato M, Schuster F et al. Viral and murine interleukin-10 are correctly processed and retain their biological activity when produced in tobacco. BMC Biotechnol.9, 22 (2009).
   Google Scholar
• Zaccone P, Phillips J, Conget I et al. Interleukin-13 prevents autoimmune diabetes in NOD mice. Diabetes48(8), 1522–1528 (1999).
   PubMed Web of Science ®Google Scholar
• Kawakami K, Kawakami M, Puri RK. Specifically targeted killing of interleukin-13 (IL-13) receptor-expressing breast cancer by IL-13 fusion cytotoxin in animal model of human disease. Mol. Cancer Ther.3(2), 137–147 (2004).
   Google Scholar
• Shimamura T, Husain SR, Puri RK. The IL-4 and IL-13 pseudomonas exotoxins: new hope for brain tumor therapy. Neurosurg. Focus20(4), E11 (2006).
   Google Scholar
• Wang DJ, Brandsma M, Yin Z, Wang A, Jevnikar AM, Ma S. A novel platform for biologically active recombinant human interleukin-13 production. Plant Biotechnol. J.6(5), 504–515 (2008).
   Google Scholar
• Sharma A, Sharma M. Plants as bioreactors: recent developments and emerging opportunities. Biotechnol. Adv.27, 811–832 (2009).
   PubMed Web of Science ®Google Scholar
• Gleba Y, Klimyuk V, Marillonnet S. Magnifection – a new platform for expressing recombinant vaccines in plants. Vaccine23(17–18), 2042–2048 (2005).
   PubMed Web of Science ®Google Scholar
• Sainsbury F, Thuenemann EC, Lomonossoff GP. pEAQ: versatile expression vectors for easy and quick transient expression of heterologous proteins in plants. Plant Biotechnol. J.7(7), 682–693 (2009).
   PubMed Web of Science ®Google Scholar
• Modelska A, Dietzschold B, Sleysh N et al. Immunization against rabies with plant-derived antigen. Proc. Natl Acad. Sci. USA95(5), 2481–2485 (1998).
   PubMed Web of Science ®Google Scholar
• Rybicki EP. Plant-made vaccines for humans and animals. Plant Biotechnol. J.8(5), 620–637 (2010).
   PubMed Web of Science ®Google Scholar
• Scheller J, Leps M, Conrad U. Forcing single-chain variable fragment production in tobacco seeds by fusion to elastin-like polypeptides. Plant Biotechnol. J.4(2), 243–249 (2006).
   PubMed Web of Science ®Google Scholar
• Joensuu JJ, Conley AJ, Lienemann M, Brandle JE, Linder MB, Menassa R. Hydrophobin fusions for high-level transient protein expression and purification in Nicotiana benthamiana. Plant Physiol.152(2), 622–633 (2010).
   PubMed Web of Science ®Google Scholar
• de Virgilio M, De Marchis F, Bellucci M et al. The human immunodeficiency virus antigen Nef forms protein bodies in leaves of transgenic tobacco when fused to zeolin. J. Exp. Bot.59(10), 2815–2829 (2008).
   Google Scholar